ArticleBritish journal of pharmacology2025
Unravelling the multifaceted actions of neurosteroids: Machine learning and in vitro screening for novel target discovery.
Article in British journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- New directions in neurosteroid therapeutics in neuropsychiatry.Neuroscience and biobehavioral reviews · 2025Review
- Neurosteroid withdrawal disrupts GABAergic system development in human cortical organoids: implications for preterm birth.Frontiers in cellular neuroscience · 2025Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
background and purposeNeurosteroids (NS) modulate neuronal function and are promising therapeutic agents for neuropsychiatric disorders. NS analogues are approved for treating postpartum depression and are of interest in other disorders. Gamma-aminobutyric acid type A (GABA EXPERIMENTAL APPROACH: We performed hypothesis-generating in silico analyses using machine learning and broad in vitro biological screens to assess the range of actions of NS analogues of varying structural attributes. We employed machine learning for molecular similarity analysis and network pharmacology to elucidate likely targets. KEY
resultsThis analysis confirmed likely targets beyond GABA CONCLUSIONS AND IMPLICATIONS: NS compounds are ascendant treatments in neuropsychiatry, but their full spectrum of actions remains unclear. This virtual and biological screening discovery approach opens new vistas for exploring the mechanism of NS analogues. The multifaceted approach provides an unbiased, holistic exploration of the potential effects of NS compounds across various molecular targets and provides a platform for future validation studies to aid drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.